Interview, Podcast
a16z Podcast | When Bio Meets Computer Science
- A convergence of advances in genomics, computer science, and sensor costs is driving an inflection point where biology and software sectors merge, enabling new startups to operate with software-like speed, low initial capital, and scalability comparable to cloud computing.
- Digital therapeutics are expected to address lifestyle-driven health issues, estimated to account for 75% of U.S. long-term health spending, by leveraging mobile devices and social networks to monitor conditions and enforce behavioral changes like diet and exercise.
- "Cloud biology" models aim to replace traditional contract research organizations with elastic, shared lab infrastructure, potentially reducing experiment costs to $500,000–$1 million while improving reproducibility by mitigating the 30% to 50% irreproducibility rate common in current experiments.
- Computational medicine will handle high-volume data from radiology and genomics to assist doctors, with specific applications in cancer treatment personalization and microbiome monitoring as sequencing costs approach zero.
- Projects like Folding@Home aim to utilize 400,000 GPUs generating 40 petaflops of power to simulate protein folding and predict drug efficacy for diseases where laboratory testing is currently insufficient.
- Computational drug repurposing strategies, such as those for infectious diseases like Ebola and Dengue, are projected to accelerate regulatory timelines from 15 years to approximately nine months.
- New bio-startups are expected to follow Moore's Law rather than traditional regulatory cost structures ("e-rooms law"), fostering an explosion of seed-stage companies with economic profiles similar to the 1980s semiconductor or 1990s internet booms.
- While high failure rates in experimental bio startups are anticipated, the ability to run significantly more low-cost experiments is predicted to yield a higher volume of overall successes.